Ubs Group Ag Cerus Corp Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

A detailed history of Ubs Group Ag transactions in Cerus Corp stock. As of the latest transaction made, Ubs Group Ag holds 242,336 shares of CERS stock, worth $395,007. This represents 0.0% of its overall portfolio holdings.

Number of Shares
242,336
Previous 230,438 5.16%
Holding current value
$395,007
Previous $405,000 3.95%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1.7 - $2.39 $20,226 - $28,436
11,898 Added 5.16%
242,336 $421,000
Q2 2024

Aug 13, 2024
SELL
$1.62 - $2.04 $192,083 - $241,882
-118,570 Reduced 33.97%
230,438 $405,000
Q1 2024

May 13, 2024
SELL
$1.66 - $2.42 $95,410 - $139,091
-57,476 Reduced 14.14%
349,008 $659,000
Q4 2023

Feb 09, 2024
BUY
$1.25 - $2.35 $125,170 - $235,319
100,136 Added 32.69%
406,484 $878,000
Q3 2023

Nov 09, 2023
SELL
$1.5 - $3.07 $28,575 - $58,483
-19,050 Reduced 5.85%
306,348 $496,000
Q2 2023

Aug 11, 2023
BUY
$1.79 - $2.9 $222,985 - $361,261
124,573 Added 62.03%
325,398 $800,000
Q1 2023

May 12, 2023
SELL
$2.65 - $3.81 $1.36 Million - $1.95 Million
-512,124 Reduced 71.83%
200,825 $596,000
Q4 2022

Feb 08, 2023
BUY
$3.38 - $4.22 $153,844 - $192,077
45,516 Added 6.82%
712,949 $2.6 Million
Q3 2022

Nov 10, 2022
SELL
$3.43 - $5.83 $2,723 - $4,629
-794 Reduced 0.12%
667,433 $2.4 Million
Q2 2022

Aug 10, 2022
SELL
$4.41 - $5.69 $44,188 - $57,013
-10,020 Reduced 1.48%
668,227 $3.54 Million
Q1 2022

May 16, 2022
SELL
$4.81 - $6.99 $115,141 - $167,326
-23,938 Reduced 3.41%
678,247 $3.72 Million
Q4 2021

Feb 14, 2022
BUY
$5.97 - $7.93 $520,195 - $690,980
87,135 Added 14.17%
702,185 $4.78 Million
Q3 2021

Nov 15, 2021
BUY
$4.79 - $6.68 $2.75 Million - $3.83 Million
573,420 Added 1377.42%
615,050 $3.75 Million
Q2 2021

Aug 13, 2021
SELL
$5.35 - $6.35 $1.02 Million - $1.21 Million
-190,303 Reduced 82.05%
41,630 $246,000
Q1 2021

May 12, 2021
BUY
$5.68 - $7.87 $369,211 - $511,565
65,002 Added 38.94%
231,933 $1.39 Million
Q4 2020

Feb 11, 2021
SELL
$5.25 - $8.56 $1.49 Million - $2.43 Million
-284,027 Reduced 62.98%
166,931 $1.16 Million
Q3 2020

Nov 12, 2020
BUY
$5.78 - $7.47 $146,216 - $188,968
25,297 Added 5.94%
450,958 $2.82 Million
Q2 2020

Jul 31, 2020
BUY
$4.5 - $7.02 $1.34 Million - $2.09 Million
297,575 Added 232.32%
425,661 $2.81 Million
Q1 2020

May 01, 2020
BUY
$2.87 - $5.49 $239,619 - $458,365
83,491 Added 187.22%
128,086 $596,000
Q4 2019

Feb 14, 2020
SELL
$3.84 - $4.86 $36,433 - $46,111
-9,488 Reduced 17.54%
44,595 $188,000
Q3 2019

Nov 14, 2019
BUY
$4.86 - $6.05 $106,511 - $132,591
21,916 Added 68.13%
54,083 $279,000
Q2 2019

Aug 14, 2019
SELL
$4.51 - $6.6 $89,090 - $130,376
-19,754 Reduced 38.05%
32,167 $181,000
Q1 2019

May 14, 2019
SELL
$5.16 - $6.85 $127,596 - $169,386
-24,728 Reduced 32.26%
51,921 $323,000
Q4 2018

Feb 14, 2019
BUY
$4.89 - $7.16 $144,665 - $211,821
29,584 Added 62.86%
76,649 $389,000
Q3 2018

Nov 14, 2018
SELL
$6.89 - $7.78 $121,642 - $137,355
-17,655 Reduced 27.28%
47,065 $339,000
Q2 2018

Aug 14, 2018
BUY
$5.19 - $7.25 $49,445 - $69,070
9,527 Added 17.26%
64,720 $432,000
Q1 2018

May 15, 2018
BUY
$3.56 - $5.74 $1,776 - $2,864
499 Added 0.91%
55,193 $302,000
Q4 2017

Feb 14, 2018
SELL
$2.76 - $3.95 $57,391 - $82,136
-20,794 Reduced 27.55%
54,694 $185,000
Q3 2017

Nov 14, 2017
BUY
$2.22 - $2.73 $44,883 - $55,195
20,218 Added 36.58%
75,488 $206,000
Q2 2017

Aug 14, 2017
BUY
N/A
157 Added 0.28%
55,270 $139,000
Q1 2017

Nov 14, 2017
BUY
N/A
55,113
55,113 $246,000

Others Institutions Holding CERS

# of Institutions
155
Shares Held
147M
Call Options Held
84.2K
Put Options Held
55.5K
View Full List

About CERUS CORP

CERS Quotes by TradingView
  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $289M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email